File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability

TitleHepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability
Authors
KeywordsHepatitis B virus
Hepatitis B surface antigen
Antibody to hepatitis B surface antigen
Covalently closed circular DNA
Antiviral
Issue Date2016
PublisherSpringer Japan. The Journal's web site is located at http://link.springer-ny.com/link/service/journals/00535/index.htm
Citation
Journal of Gastroenterology, 2016, v. 51 n. 5, p. 487-495 How to Cite?
AbstractBackground: Hepatitis B surface antigen (HBsAg) seroclearance is the recommended treatment end point for nucleoside analogue (NA) therapy in chronic hepatitis B, yet the underlying kinetics and durability of HBsAg seroclearance in NA-treated patients have not been well described. Methods: We compared the HBsAg kinetics and long-term serologic outcomes of 51 chronic hepatitis B patients achieving HBsAg seroclearance during NA therapy with those of 51 HBsAg-positive controls, matched for age, sex, hepatitis B e antigen status, NA type, and treatment duration. Viral profiles before and after HBsAg seroclearance during and after NA treatment cessation were determined. Results: The median time to HBsAg seroclearance and the median follow-up duration after HBsAg seroclearance were 61.2 and 51.6 months respectively. Patients achieving HBsAg seroclearance maintained high median rates of HBsAg reduction throughout therapy (first 6 months, 0.40 IU/mL/year; after year 1, 0.39 IU/mL/year; p = 0.809). For controls, the median rate of HBsAg reduction was significantly slower with time (first 6 months and after year 1, 0.19 and 0.05 IU/mL/year; p = 0.006). The difference in the median HBsAg reduction rates after year 1 between the two groups was significant (p < 0.001). The cumulative rates of antibody to HBsAg development and HBsAg seroreversion 72 months after HBsAg seroclearance were 68.9 and 8.3 % (one patient receiving immunosuppressive therapy; one patient with pre-S/S variant), respectively. Among 22 patients who discontinued therapy after HBsAg seroclearance, 21 remained HBsAg negative with undetectable hepatitis B virus DNA and one patient with reactivation had the pre-S/S variant. Conclusion: NA-treated patients achieving HBsAg seroclearance uniquely maintained high rates of HBsAg reduction throughout treatment, with HBsAg seroclearance durable in most of the patients after treatment cessation.
Persistent Identifierhttp://hdl.handle.net/10722/226362
ISSN
2019 Impact Factor: 6.132
2015 SCImago Journal Rankings: 1.651
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKW-
dc.contributor.authorCheung, KSM-
dc.contributor.authorWong, DKH-
dc.contributor.authorHuang, FY-
dc.contributor.authorFung, JYY-
dc.contributor.authorLiu, SHK-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2016-06-17T07:43:38Z-
dc.date.available2016-06-17T07:43:38Z-
dc.date.issued2016-
dc.identifier.citationJournal of Gastroenterology, 2016, v. 51 n. 5, p. 487-495-
dc.identifier.issn0944-1174-
dc.identifier.urihttp://hdl.handle.net/10722/226362-
dc.description.abstractBackground: Hepatitis B surface antigen (HBsAg) seroclearance is the recommended treatment end point for nucleoside analogue (NA) therapy in chronic hepatitis B, yet the underlying kinetics and durability of HBsAg seroclearance in NA-treated patients have not been well described. Methods: We compared the HBsAg kinetics and long-term serologic outcomes of 51 chronic hepatitis B patients achieving HBsAg seroclearance during NA therapy with those of 51 HBsAg-positive controls, matched for age, sex, hepatitis B e antigen status, NA type, and treatment duration. Viral profiles before and after HBsAg seroclearance during and after NA treatment cessation were determined. Results: The median time to HBsAg seroclearance and the median follow-up duration after HBsAg seroclearance were 61.2 and 51.6 months respectively. Patients achieving HBsAg seroclearance maintained high median rates of HBsAg reduction throughout therapy (first 6 months, 0.40 IU/mL/year; after year 1, 0.39 IU/mL/year; p = 0.809). For controls, the median rate of HBsAg reduction was significantly slower with time (first 6 months and after year 1, 0.19 and 0.05 IU/mL/year; p = 0.006). The difference in the median HBsAg reduction rates after year 1 between the two groups was significant (p < 0.001). The cumulative rates of antibody to HBsAg development and HBsAg seroreversion 72 months after HBsAg seroclearance were 68.9 and 8.3 % (one patient receiving immunosuppressive therapy; one patient with pre-S/S variant), respectively. Among 22 patients who discontinued therapy after HBsAg seroclearance, 21 remained HBsAg negative with undetectable hepatitis B virus DNA and one patient with reactivation had the pre-S/S variant. Conclusion: NA-treated patients achieving HBsAg seroclearance uniquely maintained high rates of HBsAg reduction throughout treatment, with HBsAg seroclearance durable in most of the patients after treatment cessation.-
dc.languageeng-
dc.publisherSpringer Japan. The Journal's web site is located at http://link.springer-ny.com/link/service/journals/00535/index.htm-
dc.relation.ispartofJournal of Gastroenterology-
dc.subjectHepatitis B virus-
dc.subjectHepatitis B surface antigen-
dc.subjectAntibody to hepatitis B surface antigen-
dc.subjectCovalently closed circular DNA-
dc.subjectAntiviral-
dc.titleHepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability-
dc.typeArticle-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailCheung, KSM: cks634@hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailHuang, FY: fungyu@hkucc.hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailLiu, SHK: drkliu@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityCheung, KSM=rp02532-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00535-015-1128-2-
dc.identifier.pmid26446756-
dc.identifier.scopuseid_2-s2.0-84944596600-
dc.identifier.hkuros258639-
dc.identifier.volume51-
dc.identifier.issue5-
dc.identifier.spage487-
dc.identifier.epage495-
dc.identifier.isiWOS:000374669500008-
dc.publisher.placeJapan-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats